ClinicalTrials.gg
RecruitingNCT06193668OVID_FASTIUpdated Mar 1, 2024

Overfeeding Induced Fat-tissue Stimulation

An interventional study of High-fat overnutrition and Normocaloric macronutrient-balanced nutrition in Lipid-induced Insulin Resistance, sponsored by German Diabetes Center. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-01.

Sponsored by German Diabetes Center · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Type 2 diabetes is the most common metabolic disease worldwide, characterized by hyperglycemia, decreased whole body insulin sensitivity, and white adipose tissue (WAT) dysfunction. A key factor in its development is chronic overnutrition, usually with a high-fat diet (HFD), leading to disturbances of glucose and lipid metabolism. However, the mechanism of short-term HFD-induced tissue-specific insulin resistance remains poorly understood. This project aims to further unravel the underlying mechanisms of short-term HFD overnutrition-mediated WAT insulin resistance. The model described here corresponds to a randomized, single- blinded parallel-grouped trial, consisting of two interventions: a macronutrient-balanced diet and or a hypercaloric diet over three weeks in order to investigate differences in interorgan fatty acid and glucose metabolism between the studied groups. Based on recent studies, the hypothesis is that 21-day hypercaloric HFD induces WAT insulin resistance via a diacylglycerol, novel protein kinase C-insulin receptor signaling model in both fasting and insulin-stimulated states.

02

Conditions studied

  • Lipid-induced Insulin Resistance

Browse trials for

03

In context

Insulin Resistance

2,969 studies on the registry are indexed under Insulin Resistance; 338 are open to participants now.

This study's planned enrollment of 32 is below the median of 40 across 2,369 interventional studies indexed under Insulin Resistance.

Browse Insulin Resistance studies →

Lead sponsor

German Diabetes Center is the lead sponsor of 30 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 40 years
  • \< 29 kg/m2
  • Sport inactive (\<1x /week)
  • Capacity to consent

Exclusion criteria

Exclusion Criteria:

  • Diabetes mellitus disease
  • Acute coronary heart syndrome (myocardial infarction, unstable angina pectoris, stroke or in the last 3 months before study participation)
  • Acute infectious disease
  • Taking blood glucose-lowering drugs
  • Diseases or drugs affecting the immune system and allergies to drugs used in the study
  • Drugs with potential metabolic effects
  • Chronic liver disease (hepatitis, gallbladder disease, elevated liver enzymes ( > 300 U/L))
  • Chronic inflammatory bowel diseases
  • Rheumatic diseases
  • Hyper- or hypothyroidism of the thyroid gland
  • Renal insufficiency, administration of iodine-containing contrast media in the last 2 days
  • Chronic lung diseases
  • cancerous diseases
  • Addictive diseases, psychiatric diseases
  • Pregnancy, breastfeeding
  • Shift workers
  • Anemia ( \<12 g/dl)
  • Disorders of hemostasis
  • Regular use of antithrombotic drugs
  • Alcohol consumption, smoking
  • Conditions that do not permit an MRI examination
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
32 participants (estimated)

Study arms

  • Active comparator
    High-fat overnutrition

    Lipid overnutrition: 40% higher lipid consumption per day than required over three weeks.

    Behavioral: High-fat overnutrition

  • Active comparator
    Normocaloric macronutrient-balanced nutrition

    Normocaloric, macronutrient-balanced nutrition per day over three weeks

    Behavioral: Normocaloric macronutrient-balanced nutrition

Interventions

  • BehavioralHigh-fat overnutrition

    Overnutrition: 40% higher lipid consumption per day than required

  • BehavioralNormocaloric macronutrient-balanced nutrition

    Normocaloric, macronutrient-balanced nutrition: Calories requirement for weight maintenance \[(kcal/d) 55% carbohydrates, 15% proteins, 30% fat\]

06

What researchers measure

Primary outcomes

  1. Whole-body insulin sensitivity and WAT insulin sensitivity

    Hyperinsulinemica-euglycemia clamp tests with deuterated glucose to measure fasting and insulin-stimulated whole-body insulin sensitivity and measurement of the index ADIPO-IR (fasting insulin x free fatty acid concentration) before and after dietary intervention period.

    Time frame: 3 weeks intervention period each

Secondary outcomes

  1. WAT insulin signaling pathways

    Adipose tissue biopsies are planned to be taken during the fasting and insulin-stimulated state before and after the dietary intervention period. DAG and ceramide subcellular fractionation assay is planned to be performed. Expressionanalyses for activation /membrane translocation of novel and atypical protein kinase C isoforms will be done. Determination of the degree of phosphorylation of various components of the insulin pathway via Western blot are planned.

    Time frame: 3 weeks intervention time

07

Study locations

1 of 1 sites recruiting
  • Georgia Xourafa
    Düsseldorf, Nordrhein-Westfalen 40225, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06193668
Lead sponsor
German Diabetes Center
Collaborators
Yale University
Responsible party
Sponsor
First posted
Jan 5, 2024
Start date
Jan 31, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Mar 1, 2024

Study contacts

Theresia Sarabhai, MD
Contact
theresia.sarabhai@ddz.de
0173-9473478 ext. DDZ
Sabine Kahl, MD
Contact
sabine.kahl@ddz.de
0221-3382- ext. 698
Michael Roden, Prof., MD
study director · German Diabetes Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion